Charles Schwab
YMAB

Charles Schwab’s Y-mAbs Therapeutics YMAB Stock Holding History

Charles Schwab’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-278,179
Closed -$1.25M – 3555
2025
Q2 		$1.25M Buy
278,179
+569
+0.2% +$2.56K ﹤0.01% 2829
2025
Q1 		$1.23M Sell
277,610
-6,930
-2% -$40.2K ﹤0.01% 2774
2024
Q4 		$2.23M Buy
284,540
+4,963
+2% +$60.4K ﹤0.01% 2641
2024
Q3 		$3.68M Buy
279,577
+23,982
+9% +$304K ﹤0.01% 2513
2024
Q2 		$3.09M Buy
255,595
+5,370
+2% +$72.5K ﹤0.01% 2551
2024
Q1 		$4.07M Buy
250,225
+2,719
+1% +$36.6K ﹤0.01% 2360
2023
Q4 		$1.69M Sell
247,506
-1,938
-0.8% -$11.2K ﹤0.01% 2668
2023
Q3 		$1.36M Sell
249,444
-7,651
-3% -$44.6K ﹤0.01% 2702
2023
Q2 		$1.75M Buy
257,095
+21,455
+9% +$161K ﹤0.01% 2591
2023
Q1 		$1.18M Sell
235,640
-15,919
-6% -$65K ﹤0.01% 2686
2022
Q4 		$1.23M Buy
251,559
+3,144
+1% +$22.8K ﹤0.01% 2713
2022
Q3 		$3.58M Buy
248,415
+807
+0.3% +$13.4K ﹤0.01% 2391
2022
Q2 		$3.75M Buy
247,608
+13,852
+6% +$162K ﹤0.01% 2310
2022
Q1 		$2.78M Sell
233,756
-10,988
-4% -$113K ﹤0.01% 2536
2021
Q4 		$3.97M Buy
244,744
+5,125
+2% +$110K ﹤0.01% 2463
2021
Q3 		$6.84M Buy
239,619
+37,500
+19% +$1.18M ﹤0.01% 2227
2021
Q2 		$6.83M Buy
202,119
+11,601
+6% +$372K ﹤0.01% 2198
2021
Q1 		$5.76M Buy
190,518
+13,042
+7% +$535K ﹤0.01% 2230
2020
Q4 		$8.79M Buy
177,476
+5,236
+3% +$242K ﹤0.01% 1937
2020
Q3 		$6.61M Buy
172,240
+31,359
+22% +$1.25M ﹤0.01% 1935
2020
Q2 		$6.09M Buy
140,881
+20,073
+17% +$759K ﹤0.01% 1927
2020
Q1 		$3.15M Buy
120,808
+2,280
+2% +$66.2K ﹤0.01% 2065
2019
Q4 		$3.7M Buy
118,528
+31,374
+36% +$928K ﹤0.01% 2180
2019
Q3 		$2.27M Buy
87,154
+21,153
+32% +$540K ﹤0.01% 2340
2019
Q2 		$1.51M Buy
66,001
+30,268
+85% +$695K ﹤0.01% 2451
2019
Q1 		$937K Sell
35,733
-1,649
-4% -$36.2K ﹤0.01% 2570
2018
Q4 		$761K Buy
+37,382
New +$858K ﹤0.01% 2619

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Charles Schwab's YMAB Position: Q3 2025 in Review

Charles Schwab sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 278,179 shares — an estimated $1.25M sold.

Charles Schwab first reported a position in YMAB in Q4 2018 and held it in 27 quarters. The position peaked at $8.79M in Q4 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • Charles Schwab reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Charles Schwab sold 278,179 Y-mAbs Therapeutics shares in Q3 2025, an estimated $1.25M.
  • Charles Schwab first reported a position in Y-mAbs Therapeutics in Q4 2018 and held it in 27 quarters.
  • Charles Schwab's Y-mAbs Therapeutics position peaked at $8.79M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Charles Schwab's 13F filing for Q3 2025, filed 10 Nov 2025.